SCHEMBL13633790

SCHEMBL13633790

Cc1nc(-c2ccncc2)oc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.50
PKM P14618 1/20 0.50
RAB9A P51151 6/20 0.44
NPC1 O15118 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ATAD2 Q6PL18 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
KDM4E B2RXH2 4/20 0.43
HSD17B10 Q99714 3/20 0.43
GAA P10253 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
STAT1 P42224 1/20 0.43
PIK3CB P42338 2/20 0.42
PIK3CA P42336 1/20 0.42
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436384 0.81 GAA (0.57) RAB9ANPC1SMN1; SMN2KDM4EGAA
SCHEMBL2706143 0.81 NPC1 (0.52) TP53RAB9ANPC1MEN1KMT2A
SCHEMBL1863083 0.80 TP53 (0.47) TP53PKMRAB9ANPC1MEN1
SCHEMBL21408734 0.79 S1PR1 (0.41) TP53RAB9ANPC1MEN1KMT2A
SCHEMBL24125061 0.78 RAB9A (0.52) TP53RAB9ANPC1MEN1KMT2A
SCHEMBL5534902 0.78 KDM4E (0.59) TP53RAB9ANPC1MEN1KMT2A
SCHEMBL14431592 0.78 GAA (0.54) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL9862893 0.78 NPC1 (0.51) PKMRAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL1557048 0.78 TARBP2 (0.53) TP53RAB9ANPC1MEN1KMT2A
SCHEMBL5543997 0.78 NPC1 (0.52) TP53RAB9ANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 TP53 3524/4885PKM 841/4885RAB9A 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.